logo
Sign in

MAKSCIENTIFIC

Watertown, MA · Biotech · Private

Peripherally acting cannabinoid receptor CB1 neutral antagonists for diabetic nephropathy treatment

Claim this profile

Follows are private to you and power your alerts

Updated · makscientific.com

Sector
Biotech
Headquarters
Watertown, MA
Total capital
$4.6M
Federal grants
$2.9M
8 awards · 2015–2025
Rank in peer group#292 of 392
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$1.6M
4 awards · Health and Human S
Rank in Biotech#151 of 4373
Granted patents
3
12 pending · first 2020
Rank in peer group#40 of 392

Capital timeline

200520092013201720212025FEDERAL ↑EQUITY ↓Cumulative $4.6M$750K$750K$646K$646K$320K$573K
200520092013201720212025FEDERAL ↑EQUITY ↓Cumulative $4.6M$750K$750K$646K$646K

Latest events

  • Federal grantHealth and Human S · Phase I · Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).$55K
  • Federal grantHealth and Human S · Phase II · A CB1 Antagonist for Treatment of Kidney Disease$573K
  • Federal grantHealth and Human S · Phase I · Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).$320K
  • Federal grantHealth and Human S · Phase I · Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases$225K
  • Federal grantHealth and Human S · Phase I · Lead Optimization of Peripheral CB1 Neutral Antagonists for Renal Diseases$225K
  • Federal grantHealth and Human S · Phase II · NAAA Inhibitors as Anti-inflammatory Agents, Phase II$646K
  • Federal grantHealth and Human S · Phase II · NAAA Inhibitors as Anti-inflammatory Agents, Phase II$646K
Show 5 earlier federal awards
  • Federal grantHealth and Human S · Phase I · NAAA Inhibitors as Anti-Inflammatory Agents$233K
  • Federal contractHealth and Human S · Igf::ot::igf Other Functionmakscientific LLC:1106515 [14-005142]$10K
  • Federal contractHealth and Human S · Novel Azetidine CB1 Antagonists$750K
  • Federal contractHealth and Human S · SBIR Phase 1 New Award N43DA-8-8874 Titled Novel Azetidine CB1 Antagonists$119K
  • Federal contractHealth and Human S · Novel CB1 Receptor Antagonists: Phase II$750K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#40 · top 10%
  • Linked publications#3 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 3 granted of 15
Show all 15 patent records
  • Pharmaceutical Compositions, and Preparation and Methods of Use ThereofDec 25, 2025 · Application 18835417Pending
  • Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid OverdoseNov 21, 2024 · Application 18779153Pending
  • Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid OverdoseAug 6, 2024 · US 12,054,480Granted
  • Process for Making Biologically Active Compounds and Intermediates ThereofMar 26, 2024 · US 11,939,325Granted
  • Novel Compounds for Treating Fibrosis and Inflammatory ConditionsJul 27, 2023 · Application 18007199Pending
  • ABHD6 And Dual ABHD6/MGL Inhibitors And Their UsesMay 26, 2020 · US 10,662,159Granted
  • Method for Treating a Neurodegenerative EventMay 19, 2016 · Application 14941821Pending
  • Composition and Method for Treating a Neurodegenerative EventOct 31, 2013 · Application 13859292Pending
  • CB1 Receptor Antagonists and Uses ThereofMay 16, 2013 · Application 13649525Pending
  • Pharmaceutical Compositions, and Preparation and Methods of Use ThereofApplication 19507038Pending
  • Pharmaceutical Compositions, And Preparation And Methods Of Use ThereofApplication PCTUS2024040447Pending
  • Pharmaceutical Compositions, And Preparation And Methods Of Use ThereofApplication PCTUS2023061889Pending
  • Novel Compounds For Treating Fibrosis And Inflammatory ConditionsApplication PCTUS2021043332Pending
  • Methods for Treating Alcohol Addiction, Alcohol-Use Disorders and Alcohol-Related Inflammatory DiseasesApplication 19528574Pending
  • Methods For Treating Alcohol Addiction, Alcohol-use Disorders And Alcohol-related Inflammatory DiseasesApplication PCTUS2024052662Pending

Recent research by its founders

  • Library Docking for Cannabinoid-2 Receptor Ligands20260 cites
  • Structural basis of THC analog activity at the Cannabinoid 1 receptor202517 cites
  • Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects202513 cites

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .